Ralinepag vs Treprostinil (L606)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Ralinepag

Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT03626688 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).

Next expected readout: December 2026 · NCT03683186 (registry estimate)

Reported efficacy

Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)

Result source: NCT03626688

Treprostinil (L606)

Developed by Liquidia Corporation under a licence from Pharmosa Biopharm Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin analogue, inhaled liposomal)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Pulmonary Arterial Hypertension

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Treprostinil (L606): no structured comparison results are available for Pulmonary Arterial Hypertension.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ralinepag

PVR Change Dyn S Cm5 -52.2 seconds
absolute change · seconds
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Time to First Clinical Worsening Event 13.04 months
time to event · months
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence · converted to months from 56.5 weeks as posted
6MWD - Change 20.9 m @ 13wk
absolute change · m
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
show 16 more results
17.6 m @ 26wk
NCT02279745 · Phase 2 · registry result, not featured evidence
22.8 m @ 39wk
NCT02279745 · Phase 2 · registry result, not featured evidence
28.5 m @ 52wk
NCT02279745 · Phase 2 · registry result, not featured evidence
16.2 m @ 65wk
NCT02279745 · Phase 2 · registry result, not featured evidence
16 m @ 78wk
NCT02279745 · Phase 2 · registry result, not featured evidence
32 m @ 91wk
NCT02279745 · Phase 2 · registry result, not featured evidence
41 m @ 104wk
NCT02279745 · Phase 2 · registry result, not featured evidence
38.5 m @ 117wk
NCT02279745 · Phase 2 · registry result, not featured evidence
21 m @ 130wk
NCT02279745 · Phase 2 · registry result, not featured evidence
17 m @ 143wk
NCT02279745 · Phase 2 · registry result, not featured evidence
47 m @ 156wk
NCT02279745 · Phase 2 · registry result, not featured evidence
24 m @ 169wk
NCT02279745 · Phase 2 · registry result, not featured evidence
53 m @ 182wk
NCT02279745 · Phase 2 · registry result, not featured evidence
20.5 m @ 195wk
NCT02279745 · Phase 2 · registry result, not featured evidence
1 m @ 208wk
NCT02279745 · Phase 2 · registry result, not featured evidence
-120 m @ 221wk
NCT02279745 · Phase 2 · registry result, not featured evidence
6MWD - Change 37 m
absolute change · m
No placebo or comparator arm
End of Study (Time of Discontinuation of Study by Sponsor)
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Output 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Index Change L/Min M2 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Pulmonary Arterial Pressure -2 mmHg
absolute change · mmHg
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
PVR 514.6 vs 512 placebo cm @ 22wk
absolute change · cm
NCT02279160 · Phase 2 · registry result, not featured evidence
6MWD - Change 36.2 vs 29.4 placebo m @ 22wk
absolute change · m
NCT02279160 · Phase 2 · registry result, not featured evidence
Available safety results

Ralinepag

Dropout rate
44.4%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
15%
NCT02279160 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
15.6%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
—
NCT02279160 · Phase 2 · registry result, not featured evidence
Serious AEs
46.7%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
10%
NCT02279160 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
headache 64.4%
diarrhoea 37.8%
pain in jaw 33.3%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
headache 77.5% (placebo 28.6%)
nausea 50% (placebo 23.8%)
diarrhoea 47.5% (placebo 14.3%)
NCT02279160 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (L606)'s landscape